Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 7/20 | 0.40 |
| ▸ | GUCY1B2 | O75343 | 11/20 | 0.39 |
| ▸ | GUCY1A2 | P33402 | 11/20 | 0.39 |
| ▸ | GUCY1A1 | Q02108 | 11/20 | 0.39 |
| ▸ | GUCY1B1 | Q02153 | 11/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3998766 | 0.89 | GUCY1B2 (0.40) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL3999066 | 0.89 | SCN9A (0.41) | GLP1RGUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL3229063 | 0.88 | GUCY1B2 (0.45) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL3994754 | 0.85 | GUCY1B2 (0.47) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL3994172 | 0.84 | SCN9A (0.44) | GLP1RGUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL4004424 | 0.83 | GUCY1B2 (0.41) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1PDE4A | |
| SCHEMBL17609344 | 0.83 | GUCY1A1 (0.38) | GLP1RGUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL4003135 | 0.83 | PTGDR2 (0.43) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1PDE4A | |
| SCHEMBL17609316 | 0.82 | GUCY1A1 (0.39) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL14952909 | 0.82 | GUCY1B2 (0.44) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2594270-A2 | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | BIP Patents (DE) | 2013-05-22 | — | — | EP | claimed |
| WO-2015095515-A1 | SGC ACTIVATORS FOR THE TREATMENT OF GLAUCOMA | NOVARTIS AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| EP-2594270-A2 | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | BIP Patents (DE) | 2013-05-22 | — | — | EP | disclosed |
| WO-2009071504-A1 | 2,6-DISUBSTITUTED PYRIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |